Advertisement
Advertisement
ACRV
Acrivon Therapeutics, Inc. Common Stock
1.98
USDSponsored
-0.05
-2.46%
May 08, 16:00 UTC -4
Closed
After-Market
1.99
+0.01
+0.56%
ACRV Earnings Reports
Positive Surprise Ratio
ACRV beat 10 of 13 last estimates.
77%
Next Report
Date of Next Report
May 20, 2026
Estimate for Q1 26 (Revenue/ EPS)
$282.20K
/-$0.53
Implied change from Q4 25 (Revenue/ EPS)
--
/+1.92%
Implied change from Q1 25 (Revenue/ EPS)
--
/+3.92%
Acrivon Therapeutics, Inc. Common Stock earnings per share and revenue
On Mar 19, 2026, ACRV reported earnings of -0.52 USD per share (EPS) for Q4 25, missing the estimate of -0.47 USD, resulting in a -9.34% surprise. Revenue reached --, compared to an expected 169.02 thousand, with a -100.00% difference. The market reacted with a +3.66% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 8 analysts forecast an EPS of -0.53 USD, with revenue projected to reach 282.20 thousand USD, implying an increase of 1.92% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Collegium Pharmaceutical, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$1.62
Actual
$1.76
Surprise
+8.43%
Xeris Biopharma Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.00
Actual
$0.01
Surprise
+296.08%
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
May 07, 2026 For Q1 26
Estimate
$0.24
Actual
$0.24
Surprise
-1.96%
SIGA Technologies Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-Actual
-$0.05
Surprise
-
Profound Medical Corp. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.25
Actual
-$0.19
Surprise
+25.75%
OmniAb, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.10
Actual
-$0.06
Surprise
+41.18%
ZOETIS INC.
Report Date
May 07, 2026 For Q1 26
Estimate
$1.63
Actual
$1.53
Surprise
-6.19%
Stevanato Group S.p.A.
Report Date
May 07, 2026 For Q1 26
Estimate
$0.10
Actual
$0.11
Surprise
+5.45%
Crinetics Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.26
Actual
-$1.23
Surprise
+2.51%
NewAmsterdam Pharma Company N.V. Ordinary Shares
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.50
Actual
-$0.40
Surprise
+20.32%
FAQ
What were Acrivon Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Acrivon Therapeutics, Inc. Common Stock reported EPS of -$0.52, missing estimates by -9.34%, and revenue of $0.00, -100% below expectations.
How did the market react to Acrivon Therapeutics, Inc. Common Stock's Q4 2025 earnings?
The stock price moved up 3.66%, changed from $1.64 before the earnings release to $1.70 the day after.
When is Acrivon Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 20, 2026.
What are the forecasts for Acrivon Therapeutics, Inc. Common Stock's next earnings report?
Based on 8
analysts, Acrivon Therapeutics, Inc. Common Stock is expected to report EPS of -$0.53 and revenue of $282.20K for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement